Twist Bioscience stock draws attention after MRD Express launch

Twist Bioscience launched its MRD Express service on Thursday, October 29, 2026, giving cancer researchers access to custom molecular residual disease panels with turnaround starting within one day. The company announced the launch in a Business Wire release.

Twist Bioscience stock traded at 116.03 euros on Lang & Schwarz at 13:31 CET on Tuesday, November 3, 2026.

Faster Personalized Cancer Research

MRD refers to small amounts of tumor-derived material that remain after cancer treatment. Twist said the new service is designed to combine the sensitivity of tumor-informed testing, which uses an individual tumor's variants, with timelines closer to tumor-naive testing.

The panels support oncology research, biomarker discovery and assay development. Twist said each panel can include up to 10,000 probes, while bioinformatics support, ecommerce ordering and application programming interfaces are intended to support customer workflows at different stages.

The product launch gives Twist another offering for liquid biopsy and MRD research customers. Management also highlighted manufacturing and automation improvements in its existing high-throughput environment, while noting that future demand and performance remain subject to the risks outlined in the release.

Results Set For November 12

Twist Bioscience said it will publish fiscal 2026 fourth-quarter and full-year results before the market opens on Thursday, November 12, 2026. The reporting period ended September 30, and the company plans an investor conference call at 8:00 a.m. Eastern Time.

The Euro Stoxx 50 market backdrop remains a wider factor for investor sentiment, although it does not establish a company-specific price effect.

Investors will next focus on the November 12 results for evidence of demand, financial performance and management's outlook. Follow more news and analyses on Twist Bioscience stock.

For the latest trading level, use the real-time quote of Twist Bioscience stock.